China SXT Pharmaceuticals, Inc. - Class A Ordinary Shares (SXTC)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- P/B of 0.05 — trading below book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -20.9%
China SXT Pharmaceuticals, Inc. - Class A Ordinary Shares (SXTC) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $1 million . Key value metrics: P/B ratio 0.05, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
China SXT Pharmaceuticals, Inc. - Class A Ordinary Shares — Fundamental Analysis Summary
On financial health, SXTC shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -20.9% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.03.
StockPik's composite Value Score for SXTC is 65/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
SXTC reports a solid gross margin of 59.4% (sector average: 39.4%) and a negative operating margin of -46.0%.
SXTC shows revenue declining at 2% year-over-year, with earnings declining at 88%.